Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes
To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactat...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2014-09, Vol.34 (9), p.5079-5082 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5082 |
|---|---|
| container_issue | 9 |
| container_start_page | 5079 |
| container_title | Anticancer research |
| container_volume | 34 |
| creator | Rades, Dirk Sehmisch, Lena Huttenlocher, Stefan Blank, Oliver Hornung, Dagmar Terheyden, Patrick Gliemroth, Jan Schild, Steven E |
| description | To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma.
Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS.
The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046).
SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561129532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1561129532</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-c898343f7e0eb24a6a59b60ff841c80f54618a0a99312fd8d6bb4fff12346b203</originalsourceid><addsrcrecordid>eNo1kF1LxDAQRYMg7rr6FySPvhTy0WYb32TxCxYE0ecyaSZLpUlq0iL77w24CwOXuRyGw1yQNd9qXm0byVbkOudvxpTSrbwiK9EIJpiu1yR-gB1iXtIB05HCGANSFxPllaQBf8djZQc4hJjRUpNgCNTjDLkMZupS9GUfIUQPD3TwE_QzjY7awtMY6JwQZo-hlMvcR4_5hlw6GDPennJDvp6fPnev1f795W33uK8mwflc9W0RraXbIkMjalDQaKOYc23N-5a5pla8BQZaSy6cba0ypnbOcSFrZQSTG3L_f3dK8WfBPHd-yD2OxRXjkjveKM6FbqQo6N0JXYxH201p8JCO3flJ8g-ThWMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561129532</pqid></control><display><type>article</type><title>Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Rades, Dirk ; Sehmisch, Lena ; Huttenlocher, Stefan ; Blank, Oliver ; Hornung, Dagmar ; Terheyden, Patrick ; Gliemroth, Jan ; Schild, Steven E</creator><creatorcontrib>Rades, Dirk ; Sehmisch, Lena ; Huttenlocher, Stefan ; Blank, Oliver ; Hornung, Dagmar ; Terheyden, Patrick ; Gliemroth, Jan ; Schild, Steven E</creatorcontrib><description>To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma.
Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS.
The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046).
SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 25202094</identifier><language>eng</language><publisher>Greece</publisher><subject>Aged ; Aged, 80 and over ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Brain Neoplasms - secondary ; Brain Neoplasms - surgery ; Female ; Humans ; Male ; Melanoma - pathology ; Middle Aged ; Prognosis ; Radiation Dosage ; Radiosurgery ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Anticancer research, 2014-09, Vol.34 (9), p.5079-5082</ispartof><rights>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25202094$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rades, Dirk</creatorcontrib><creatorcontrib>Sehmisch, Lena</creatorcontrib><creatorcontrib>Huttenlocher, Stefan</creatorcontrib><creatorcontrib>Blank, Oliver</creatorcontrib><creatorcontrib>Hornung, Dagmar</creatorcontrib><creatorcontrib>Terheyden, Patrick</creatorcontrib><creatorcontrib>Gliemroth, Jan</creatorcontrib><creatorcontrib>Schild, Steven E</creatorcontrib><title>Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma.
Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS.
The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046).
SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain Neoplasms - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Melanoma - pathology</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Radiation Dosage</subject><subject>Radiosurgery</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kF1LxDAQRYMg7rr6FySPvhTy0WYb32TxCxYE0ecyaSZLpUlq0iL77w24CwOXuRyGw1yQNd9qXm0byVbkOudvxpTSrbwiK9EIJpiu1yR-gB1iXtIB05HCGANSFxPllaQBf8djZQc4hJjRUpNgCNTjDLkMZupS9GUfIUQPD3TwE_QzjY7awtMY6JwQZo-hlMvcR4_5hlw6GDPennJDvp6fPnev1f795W33uK8mwflc9W0RraXbIkMjalDQaKOYc23N-5a5pla8BQZaSy6cba0ypnbOcSFrZQSTG3L_f3dK8WfBPHd-yD2OxRXjkjveKM6FbqQo6N0JXYxH201p8JCO3flJ8g-ThWMg</recordid><startdate>201409</startdate><enddate>201409</enddate><creator>Rades, Dirk</creator><creator>Sehmisch, Lena</creator><creator>Huttenlocher, Stefan</creator><creator>Blank, Oliver</creator><creator>Hornung, Dagmar</creator><creator>Terheyden, Patrick</creator><creator>Gliemroth, Jan</creator><creator>Schild, Steven E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201409</creationdate><title>Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes</title><author>Rades, Dirk ; Sehmisch, Lena ; Huttenlocher, Stefan ; Blank, Oliver ; Hornung, Dagmar ; Terheyden, Patrick ; Gliemroth, Jan ; Schild, Steven E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-c898343f7e0eb24a6a59b60ff841c80f54618a0a99312fd8d6bb4fff12346b203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain Neoplasms - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Melanoma - pathology</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Radiation Dosage</topic><topic>Radiosurgery</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rades, Dirk</creatorcontrib><creatorcontrib>Sehmisch, Lena</creatorcontrib><creatorcontrib>Huttenlocher, Stefan</creatorcontrib><creatorcontrib>Blank, Oliver</creatorcontrib><creatorcontrib>Hornung, Dagmar</creatorcontrib><creatorcontrib>Terheyden, Patrick</creatorcontrib><creatorcontrib>Gliemroth, Jan</creatorcontrib><creatorcontrib>Schild, Steven E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rades, Dirk</au><au>Sehmisch, Lena</au><au>Huttenlocher, Stefan</au><au>Blank, Oliver</au><au>Hornung, Dagmar</au><au>Terheyden, Patrick</au><au>Gliemroth, Jan</au><au>Schild, Steven E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2014-09</date><risdate>2014</risdate><volume>34</volume><issue>9</issue><spage>5079</spage><epage>5082</epage><pages>5079-5082</pages><eissn>1791-7530</eissn><abstract>To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma.
Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS.
The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046).
SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.</abstract><cop>Greece</cop><pmid>25202094</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2014-09, Vol.34 (9), p.5079-5082 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1561129532 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Aged Aged, 80 and over Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - secondary Brain Neoplasms - surgery Female Humans Male Melanoma - pathology Middle Aged Prognosis Radiation Dosage Radiosurgery Retrospective Studies Treatment Outcome |
| title | Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A40%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiosurgery%20alone%20for%201-3%20newly-diagnosed%20brain%20metastases%20from%20melanoma:%20impact%20of%20dose%20on%20treatment%20outcomes&rft.jtitle=Anticancer%20research&rft.au=Rades,%20Dirk&rft.date=2014-09&rft.volume=34&rft.issue=9&rft.spage=5079&rft.epage=5082&rft.pages=5079-5082&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1561129532%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1561129532&rft_id=info:pmid/25202094&rfr_iscdi=true |